Dr. Atkins Discusses Response to Atezolizumab in RCC

Video

In Partnership With:

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma (RCC).

Data presented by David McDermott, MD, showed that there was a relationship between tumor microenvironment factors and efficacy with atezolizumab in RCC.

In the tumors that were T-effector high and myeloid low, atezolizumab alone or with bevacizumab (Avastin) showed better efficacy compared with sunitinib (Sutent). Conversely, in the T-effector high, myeloid-high subset, atezolizumab monotherapy did poorly, but did well with the addition of bevacizumab. This suggests that bevacizumab enhances the immune responsiveness of atezolizumab, says Atkins.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,